MAIA Biotechnology Files 8-K: Material Agreement, Equity Sales
Ticker: MAIA · Form: 8-K · Filed: Oct 14, 2025 · CIK: 1878313
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-event
TL;DR
MAIA Bio inked a big deal & sold stock on Oct 13th. Details in 8-K.
AI Summary
On October 13, 2025, MAIA Biotechnology, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. Further details regarding these transactions and events are provided in the filing.
Why It Matters
This filing indicates significant corporate activity for MAIA Biotechnology, including a new material agreement and equity transactions, which could impact its financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.
Key Players & Entities
- MAIA Biotechnology, Inc. (company) — Registrant
- October 13, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 444 West Lake Street, Suite 1700 (address) — Principal executive offices
- Chicago, IL 60606 (address) — Principal executive offices
- 312-416-8592 (phone_number) — Registrant's telephone number
FAQ
What type of material definitive agreement did MAIA Biotechnology, Inc. enter into?
The filing states that MAIA Biotechnology, Inc. entered into a material definitive agreement, but the specific details of the agreement are not disclosed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on October 13, 2025.
What are the principal executive offices of MAIA Biotechnology, Inc.?
The principal executive offices of MAIA Biotechnology, Inc. are located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.
What is the standard industrial classification for MAIA Biotechnology, Inc.?
The standard industrial classification for MAIA Biotechnology, Inc. is Pharmaceutical Preparations [2834].
What other items are reported in this 8-K filing besides the material definitive agreement?
In addition to the entry into a material definitive agreement, the filing also reports on unregistered sales of equity securities and other events.
Filing Stats: 982 words · 4 min read · ~3 pages · Grade level 12.5 · Accepted 2025-10-14 09:00:46
Key Financial Figures
- $0.0001 — f the Company's common stock, par value $0.0001 per share (" Common Stock "), and (ii)
- $1 — a purchase price per Investor Share of $1.22, for an aggregate purchase price of
- $736,600 — gregate purchase price of approximately $736,600. The Investor Warrants are exercisabl
Filing Documents
- form8-k.htm (8-K) — 46KB
- ex4-1.htm (EX-4.1) — 102KB
- ex10-1.htm (EX-10.1) — 428KB
- ex99-1.htm (EX-99.1) — 12KB
- 0001493152-25-017948.txt ( ) — 869KB
- maia-20251013.xsd (EX-101.SCH) — 3KB
- maia-20251013_lab.xml (EX-101.LAB) — 33KB
- maia-20251013_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 14, 2025 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer 3